Maistering B.V & Mesterbakeren AS Sign a 5-year Digital Transformation Deal
28.1.2021 10:00:00 EET | Business Wire | Press release
Maistering, a global provider of an AI-infused business orchestration platform, today announced a strategic 5-year digital partnership with Mesterbakeren™.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210127006094/en/
Mesterbakeren™, headquartered in Oslo, Norway are the leading bakers offering the best in bread and bakery products to over 600 stores all over Norway.
As part of this engagement, Maistering, through its artificial intelligence platform, Master Collections, will deliver a complete 360° business view through enhanced collaboration with Mesterbakeren’s factories, partners and retail stores. The new platform augments leadership and teams with digital grip through AI-infused engines for insight, collaboration, creation, execution and governance.
Master Collections by Maistering is curated to enrich and speed up transformation initiatives. It allows leaders to plot and execute magical business journeys on the fly to improve, transform and innovate. The platform supports a fully virtual organization in a post-Covid world.
“Master Collections is a unique platform that helps enterprises orchestrate Journeys to reinvent themselves and shape value for customers, staff and partners. It will put AI-rich services and deep content at the fingertips of the Mesterbakeren™ team,” said Maistering CEO, John Brahim.
“After a two-month pilot with Maistering, we were convinced that Master Collections is the right platform for our digital transformation in our entire business from bakeries to customers. With Master Collections we radically shortened the introduction of a new product quality process. Our mission to be the leading bakery in Norway, inspiring, simple and best in taste, will be reinforced by going digital with Maistering,” added Tor Søreide Sivertsen, CEO of Mesterbakeren AS.
About Maistering B.V
Maistering is a global provider of an Enterprise SaaS business orchestration platform. An innovator that nurtures the innocence and energy of a millennial start-up with the deep, proven experience of business insights veterans. Headquartered in The Netherlands and supported by the uniquely designed CXO lab in Amsterdam, an AI hotspot, Maistering R&D sites are located in Bangalore (India), Rotterdam (Netherlands) and Valencia (Spain).
For additional information, please visit https://www.maistering.com/
About Mesterbakeren AS
Mesterbakeren™ delivers fresh baked goods to REMA 1000 in Norway. 20 bakeries supply retail stores all over the country with fresh bread, buns and rolls every day. The company targets to offer the best quality to Norwegian consumers, without costing more.
For additional information, please visit https://www.mesterbakeren.no/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210127006094/en/
Contact information
Maistering B.V
Vinutha Naik
Marketing Director
Vinutha.naik@maistering.com
Mesterbakeren AS
Steinar Bøe
IT Manager
steinar.boe@mesterbakeren.no
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom